Functional characterization of a 48 kDa Trypanosoma brucei cap 2 RNA methyltransferase

Megan P. Hall and C. Kiong Ho*

Department of Biological Sciences, State University of New York at Buffalo, Buffalo, NY 14260, USA

Received June 14, 2006; Revised and Accepted July 20, 2006

ABSTRACT

Kinetoplastid mRNAs possess a unique hypermethylated cap 4 structure derived from the standard m7GpppN cap structure, with 2'-O methylations on the first four ribose sugars and additional base methylations on the first adenine and the fourth uracil. While the enzymes responsible for m7GpppN cap 0 formations has been characterized in Trypanosoma brucei, the mechanism of cap 4 methylation and the role of the hypermethylated structure remain unclear. Here, we describe the characterization of a 48 kDa T. brucei 2'-O nucleoside methyltransferase (TbCom1). Recombinant TbCom1 transfers the methyl group from S-adenosylmethionine (AdoMet) to the 2'-OH of the second nucleoside of m7GpppNpNp-RNA to form m7GpppNpNmp-RNA. TbCom1 is also capable of converting cap 1 RNA to cap 2 RNA. The methyl transfer reaction is dependent on the m7GpppN cap, as the enzyme does not form a stable interaction with GpppN-terminated RNA. Mutational analysis establishes that the TbCom1 and vaccinia virus VP39 methyltransferases share mechanistic similarities in AdoMet- and cap-recognition. Two aromatic residues, Tyr18 and Tyr187, may participate in base-stacking interactions with the guanine ring of the cap, as the removal of each of these aromatic side-chains abolishes cap-specific RNA-binding.

INTRODUCTION

The 5' cap of eukaryotic mRNAs is essential for protecting mRNA from degradation and facilitating translation initiation. The simplest cap structure, m7GpppN or cap 0, consists of an N-7 methylated guanosine linked by a 5'–5' triphosphate bridge to the first nucleoside of nascent transcripts. In higher eukaryotes, including mRNAs from insects, vertebrates and their viruses, cap 0 is further modified by the addition of methyl groups to either the ribose or base moiety of the first and the second transcribed nucleosides [reviewed in (1)]. Methylation at the 2'-hydroxyl position of the first transcribed ribose is termed cap 1 (m7GpppNm) and similar methylation of the second transcribed position is termed cap 2 (m7GpppNmNm). While cap-specific 2'-O nucleoside RNA methyltransferases have been identified from viral sources and the activity has been detected in mammalian extracts (2–5), the significance of the methylated cap structure and the role of these methyltransferases in cellular mRNA metabolism remain largely unexplored.

Trypanosoma brucei and other related kinetoplastids possess a unique hypermethylated cap structure called cap 4, which consists of a standard cap 0 with 2'-O methylations on the first four ribose sugars (A mAmCmUm), and additional base methylations on the first adenine (m6,6A) and the fourth uracil (m3U) (6,7). The cap 4 structure is formed exclusively on the spliced leader (SL) RNA and is transferred to individual pre-mRNAs derived from a polycistronic transcript by trans-splicing to form mature mRNAs (8–10). Analysis of SL RNA biogenesis suggests that cap 4 is derived from cap 0 and is formed cotranscriptionally by sequential methylation in a 5'–3' direction, and that the methylation steps that lead to cap 4 are required for the trans-splicing reaction (7,11,12). Recently, a T. brucei nuclear cap-binding protein (TbCbc), which facilitates mRNA maturation and translation, was found to bind to cap 4 RNA with higher affinity than cap 0 RNA (13). These findings suggest that cap 4 plays an important role in mRNA biogenesis in trypanosomes, although it does not appear to be required for SL RNA stability, ribonucleoprotein particle assembly, or formation of SL RNA secondary structure in vivo (12).

A comprehensive genomic sequence analysis of 2'-O RNA methyltransferase family members identified two open reading frames in the T. brucei genome, Tb11.02.2500 (48 kDa) and Tb09.211.3130 (57 kDa), that resemble the vaccinia virus VP39 protein (14). VP39 is a prototype of cap-dependent 2'-O nucleoside methyltransferases; it transfers a methyl group from AdoMet to the ribose 2'-OH of the first transcribed nucleoside of viral mRNA to form cap 1 (15). Over twenty X-ray crystal structures of the VP39 protein have been solved complexed with AdoMet, S-adenosylhomocysteine (AdoHcy), cap analogues and m7Gppp(A)5 oligomers, as well as various methylated nucleotides.

*To whom the correspondence should be addressed. Tel: +1 716 645 2363; Fax: +1 716 645 2975; Email: kiongho@buffalo.edu

© 2006 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
(16–20). Residues that contact AdoMet and the m’G moiety in the VP39 co-crystal structures are conserved in the 48 and 57 kDa T. brucei proteins, suggesting that these T. brucei proteins may be responsible for SL RNA cap 4 formation.

In this study, we present biochemical characterization of the 48 kDa T. brucei protein’s cap-dependent 2’-O methyltransferase activity. We named this protein TbCom1 (T. brucei cap 2’-O methyltransferase) to denote the enzyme’s function. TbCom1 homologs are encoded in Trypanosoma cruzi (TcCom1) and Leishmania major (LmCom1) (Figure 1).

Recombinant TbCom1 binds specifically to m7GpppN- secondary structure of VP39 is indicated below the aligned sequences. The sequence were mutated to alanine in this study are denoted by asterisks above the sequence.

The Tb11.02.2500 (TbCOM1) open reading frame was amplified by PCR from total Trypanosoma brucei brucei genomic DNA (a gift from Laurie Read, SUNY Buffalo) using oligonucleotide primers designed to introduce an NdeI restriction site at the predicted translation start codon and a BglII site 3’ of the predicted stop codon. The 1.3 kb PCR product was digested with NdeI and BglII and inserted into pET16b (Novagen) to generate the plasmid pET-TbCOM1. In this context, TbCOM1 is fused in frame with a 20 amino acid N-terminal leader peptide containing 10 tandem histidines and expression of the His-tagged protein is driven by the T7 RNA polymerase promoter. The predicted amino acid sequence of the 417 amino acid TbCom1 protein is shown in Figure 1.

Alanine-substitution mutations were introduced into the TbCOM1 gene by PCR using the two-stage overlap extension method. The residues targeted for alanine-mutagenesis include Tyr18, His74, Val115, Asp142, Arg144, Tyr187, Asp192 and Gln253. The pET-TbCOM1 plasmid was used as the template for the first-stage amplifications. The DNA products of the second-stage amplification were digested with NdeI and BglII and inserted into pET16b. The presence of the desired mutation was confirmed by DNA sequencing analysis, and the presence of unwanted mutations was excluded by sequencing the entire gene.

Wild-type and mutant pET-TbCOM1 were transformed into Escherichia coli BL21(DE3) Gold (Novagen). A 2 l culture of E. coli BL21(DE3) Gold/pET-TbCOM1 was grown at 37°C in Luria–Bertani medium (LB medium) containing 0.1 mg/ml ampicillin until the OD600 reached 0.4. Isopropyl-D-thiogalactopyranoside (IPTG) was added to 0.4 mM and growth was continued at 17°C for 18 h. Cells were harvested by centrifugation and stored at −80°C. All subsequent procedures were performed at 4°C. Thawed bacteria were resuspended in 100 ml of Buffer A [50 mM Tris–HCl (pH 7.5), 10% sucrose and 0.25 M NaCl] and lysed by the addition of lysozyme and Triton X-100 to final concentrations of 100 μg/ml and 0.1%, respectively. The lysate was sonicated to reduce viscosity, and insoluble material was removed by centrifugation for 45 min at 14,000 r.p.m. in a Beckman JA14–50 rotor. The soluble extract was applied to a 5 ml column of Ni-NTA-agarose resin (Qiagen) that had been pre-equilibrated with Buffer A containing 0.1% Triton X-100.

The Tb11.02.2500 (TbCOM1) open reading frame was amplified by PCR from total Trypanosoma brucei brucei genomic DNA (a gift from Laurie Read, SUNY Buffalo) using oligonucleotide primers designed to introduce an NdeI restriction site at the predicted translation start codon and a BglII site 3’ of the predicted stop codon. The 1.3 kb PCR product was digested with NdeI and BglII and inserted into pET16b (Novagen) to generate the plasmid pET-TbCOM1. In this context, TbCOM1 is fused in frame with a 20 amino acid N-terminal leader peptide containing 10 tandem histidines and expression of the His-tagged protein is driven by the T7 RNA polymerase promoter. The predicted amino acid sequence of the 417 amino acid TbCom1 protein is shown in Figure 1.

Alanine-substitution mutations were introduced into the TbCOM1 gene by PCR using the two-stage overlap extension method. The residues targeted for alanine-mutagenesis include Tyr18, His74, Val115, Asp142, Arg144, Tyr187, Asp192 and Gln253. The pET-TbCOM1 plasmid was used as the template for the first-stage amplifications. The DNA products of the second-stage amplification were digested with NdeI and BglII and inserted into pET16b. The presence of the desired mutation was confirmed by DNA sequencing analysis, and the presence of unwanted mutations was excluded by sequencing the entire gene.

Wild-type and mutant pET-TbCOM1 were transformed into Escherichia coli BL21(DE3) Gold (Novagen). A 2 l culture of E. coli BL21(DE3) Gold/pET-TbCOM1 was grown at 37°C in Luria–Bertani medium (LB medium) containing 0.1 mg/ml ampicillin until the OD600 reached 0.4. Isopropyl-D-thiogalactopyranoside (IPTG) was added to 0.4 mM and growth was continued at 17°C for 18 h. Cells were harvested by centrifugation and stored at −80°C. All subsequent procedures were performed at 4°C. Thawed bacteria were resuspended in 100 ml of Buffer A [50 mM Tris–HCl (pH 7.5), 10% sucrose and 0.25 M NaCl] and lysed by the addition of lysozyme and Triton X-100 to final concentrations of 100 μg/ml and 0.1%, respectively. The lysate was sonicated to reduce viscosity, and insoluble material was removed by centrifugation for 45 min at 14,000 r.p.m. in a Beckman JA14–50 rotor. The soluble extract was applied to a 5 ml column of Ni-NTA-agarose resin (Qiagen) that had been pre-equilibrated with Buffer A containing 0.1% Triton X-100.

The column was washed with 50 ml of the same buffer and eluted stepwise with 15 ml aliquots of Buffer B [50 mM Tris–HCl (pH 8.0), 0.25 M NaCl and 10% glycerol] containing 0.05, 0.1, 0.2, 0.5 or 1 M imidazole. The polypeptide composition of the column fractions was monitored by SDS–PAGE. The His-tagged TbCom1 proteins adsorbed to the column and were recovered in 0.1, 0.2 and 0.5 M imidazole eluates. These fractions were pooled and adjusted to 0.025 M NaCl by addition of Buffer C [50 mM Tris–HCl (pH 8.0) and 10% glycerol], and then applied to a 5 ml column of diethylaminoethyl (DEAE) cellulose pre-equilibrated in Buffer C containing 0.025 M NaCl. TbCom1 did not bind to DEAE at low ionic strength but many of the bacterial polypeptides were eluted during this step. The DEAE
flowthrough fraction was applied to a 5 ml phosphocellulose column pre-equilibrated in Buffer B with 0.025 M NaCl. The column was washed with 50 ml of the same buffer and then eluted stepwise with 15 ml of Buffer B containing 0.05, 0.1, 0.2, 0.3, 0.5 and 1.0 M NaCl. TbCom1 was recovered predominantly in the 0.2 M NaCl fraction (~5 mg). The protein sample was concentrated using Amicon-Ultra centrifugal filter devices (Millipore) to 2.4 mg/ml, stored at ~80°C and thawed on ice just prior to use. Protein concentrations were determined with the Bio-Rad dye reagent using BSA as the standard.

Expression and purification of the vaccinia virus VP39 protein

The VP39 expression plasmid, pET42a-J3R, was a generous gift from Ed Niles (SUNY Buffalo). pET42a-J3R was introduced into E.coli BL21(DE3) Gold and grown at 37°C in LB medium containing 0.1 mg/ml ampicillin until the OD600 reached 0.4. The culture was adjusted to 0.4 mM IPTG and incubation was continued for 4 h. VP39 was purified from soluble bacterial lysate by one-step nickel-agarose chromatography. The 0.2 M imidazole eluate fractions containing VP39 (2.8 mg/ml) were stored at ~80°C and thawed on ice just prior to use.

Preparation of RNA substrates

Triphosphate-terminated [α-32P]GTP-labeled RNAs were synthesized by in vitro transcription from PCR amplified linear DNA templates containing the T7 RNA polymerase promoter in the presence of 2 mM [α-32P]GTP, ATP, CTP and UTP. RNAs were purified on a non-denaturing 8% polyacrylamide gel. The m 7GpppGm migrated slightly faster than m 7GpppG in 0.5 M NaCl whereas m 7GpppGm migrated slightly faster than m 7GpppG in 1.0 M NaCl. TbCom1 was recovered predominantly in the 0.2 M NaCl fraction (~24 mg). The protein sample was concentrated using Amicon-Ultra centrifugal filter devices (Millipore) to 2.4 mg/ml, stored at ~80°C and thawed on ice just prior to use. Protein concentrations were determined with the Bio-Rad dye reagent using BSA as the standard.

RESULTS

Cap-dependent RNA methyltransferase activity of TbCom1

We expressed the TbCom1 protein in E.coli as a His10-tagged fusion and purified from a soluble extract by adsorption to Ni-agarose and phosphocellulose chromatography (Materials and Methods). To evaluate whether recombinant TbCom1 possesses cap-dependent RNA methyltransferase activity, we synthesized 35mer cap 0- and cap 1-terminated RNA substrates that contain radiolabeled 5’-phosphates only at the first four transcribed nucleosides, designated as cap 0 RNA-IV and cap 1 RNA-IV, respectively (Figure 2). Digestion of cap 0 RNA-IV with nuclease P1 followed by 2D TLC resulted in two radiolabeled spots corresponding to pG and m’GppG (Figure 2A). Note that the radioactivity of pG is derived from the 5’-phosphate of nucleosides 2, 3 and 4 and thus the intensity is 3-fold greater than that of m’GppG. We verified that the positions of these spots correspond to pG and m’GppG by Ultraviolet (UV) shadowing non-radioactive nucleoside 5’-pG and m’GppG. Similarly, digestion of cap 1 RNA-IV resulted in two radiolabeled spots, corresponding to pG and m’GppG (Figure 2C). The m’GppGm migrated slightly faster than m’GppG in the first dimension due to methylation at position 1 of the transcribed RNA.

Incubation of recombinant TbCom1 with cap 0 RNA-IV in the presence of AdoMet followed by treatment with nuclease
P1 resulted in the appearance of a new radiolabeled spot that migrated faster than pG in the first dimension (compare Figure 2A and B). Approximately one-third of the pG radioactivity was converted to the new radiolabeled species, whereas the radioactivity of m7GpppG remained constant. Based on the published 2D map of methylated guanosine nucleotides (23), we assigned this spot as pGm. An identical pGm spot was detected when cap 1 RNA-IV was incubated with TbCom1 (Figure 2D), suggesting that TbCom1 is not methylating the first transcribed nucleoside. We surmise that TbCom1 is capable of modifying either cap 0 or cap 1 RNA.

TbCom1 methylates the 2nd position of transcribed RNA

To determine the site of RNA methylation by TbCom1, we synthesized three additional cap 0 RNAs containing radiolabeled phosphates at positions 1, 2 and 3 of the transcribed RNA (designated cap 0 RNA-I, -II and -IV; Figure 3A). TbCom1 was incubated with these capped RNAs in the presence of AdoMet and then treated with either nuclease P1 or an RNase cocktail. The digested products were resolved on a high percentage denaturing polyacrylamide gel. In the control reaction, digestion of cap 0 RNA-IV with nuclease P1 generated m7GpppG (Figure 3B; lanes 1, 4, 7 and 10). Addition of VP39 prior to nuclease P1 digestion shifts the m7GpppG to a slower-migrating band corresponding to the m7GpppGm cap 1 structure (Figure 3B; lanes 2, 8 and 11). Incubation of TbCom1 with any of the cap 0 RNA substrates did not alter the mobility of m7GpppG (Figure 3B; lanes 1, 6 and 9), consistent with the 2D TLC result that TbCom1 does not modify the nucleoside at position 1. When cap 0 RNA-II, -III or -IV was incubated with TbCom1, a novel radiolabeled species...
appeared which migrated between m\textsuperscript{7}GpppG and pG (Figure 3B; lanes 6, 9 and 12). This radiolabeled species likely corresponds to methylated pG (pGm), as the appearance of this band was dependent on the addition of AdoMet (data not shown). Furthermore, treatment with alkaline phosphatase after nuclease P1 digestion eliminated this species (data not shown). The methyl transfer reaction was specific to cap 0- and cap 1-terminated RNA. No detectable methylation was observed using an RNA substrate lacking the cap N-7 methyl group (Figure 4A and data not shown).

To determine if modification occurs at the 2'-hydroxyl of the ribose sugar, identical reactions were digested with an RNase cocktail and the products were similarly resolved on a polyacrylamide gel (Figure 3C). Note that methylation at the 2'-hydroxyl of the ribose will prevent digestion by RNase resulting in the generation of a longer RNA fragment. In a control reaction, RNase cleaves all four cap 0 RNA sub-strates and generates m\textsuperscript{7}GpppGp (Figure 3C; lanes 1, 4, 7 and 10). The 3'-phosphate shifts the migration of the cap dinucleotide to a faster migrating band compared to m\textsuperscript{7}GpppG. Methylation at the first nucleoside by VP39 protects the RNA from digestion between nucleosides 1 and 2, producing the cap 1 products m\textsuperscript{7}GpppGmpUp (Figure 3C, lane 2) or m\textsuperscript{7}GpppGmpGp (Figure 3C, lanes 5, 8 and 11). Note that the difference in mobility of the cap 1 products is due to the difference in nucleoside composition at position 2 (uracil versus guanine). As expected, incubation of TbCom1 with any of the cap 0 RNAs did not alter the mobility of m\textsuperscript{7}GpppGp, further confirming that methylation does not take place on the first transcribed nucleoside (Figure 3C, lanes 3, 6, 9 and 12). When TbCom1 was incubated with cap 0 RNA-I\text{II}, a radiolabeled fragment which migrated slower than m\textsuperscript{7}GpppGmpG was detected (Figure 3C, lane 9). We predict that this TbCom1 specific fragment corresponds to a methylated dinucleoside (G\text{2mGpG}p), derived from nucleosides 2 and 3, that was resistant to RNase digestion due to 2'-O methylation. An identical radiolabeled product was detected when cap 0 RNA-IV was incubated with TbCom1 (Figure 3C, lane 12).

To address whether TbCom1 can methylate nucleosides other than guanosine, we substituted the guanosine at position 2 of the cap 0 RNA-IV with either U or C to obtain m\textsuperscript{7}GppGmpUpGp and m\textsuperscript{7}GppGmpCpGp RNA. Incubation of TbCom1 with these substrates followed by treatment with RNase results in the formation of C\text{2mUpC}p and U\text{2mCpC}p dinucleotide products, respectively (data not shown). Furthermore, TbCom1 was capable of methylating the 2'-OH of the second transcribed nucleoside of either cap 0- or cap 1-terminated poly(A) (data not shown). Taken together, we surmise that TbCom1 is a cap-dependent, sequence-independent, 2'-O nucleoside methyltransferase that specifically methylates the 2nd position of a transcribed RNA.

**Characterization of TbCom1 2'-O methyltransferase activity**

The extent of nucleoside 2'-O methylation on cap 0- and cap 1-RNA during a 30 min incubation at 27°C was proportional to input TbCom1 (Figure 4A). In the linear range of enzyme dependence, we estimate ~1.5 pmol of cap 0 RNA can be methylated by 1 pmol of input enzyme in 30 min. The specific activity for methylating cap 1 RNA was ~5-fold higher compared to cap 0 RNA. TbCom1 was unable to transfer the methyl group to unmethylated capped RNA at the enzyme concentration sufficient to methylate the entire input cap 1 RNA. Methylation was dependent on AdoMet concentration from 0.1 to 0.5 mM and the yield of methylated product plateaued above 1 mM AdoMet (Figure 4B). Increasing concentration of AdoHcy in the reaction inhibited product formation; ~75% inhibition was achieved at 200 μM AdoHcy in the presence of 50 μM AdoMet (Figure 4C). TbCom1 had a bell-shaped pH profile with optimal activity between pH 7.0–7.5 and activity declined sharply at acidic pH (Figure 4D).

**Specificity of TbCom1 binding to m\textsuperscript{7}Gppp-terminated RNA**

To investigate whether TbCom1 specifically interacts with the cap structure, binding of TbCom1 to \textsuperscript{32}P-labeled cap 0 and unmethylated capped RNA was examined using a native gel mobility shift assay (Figure 5A). Binding reactions were performed in the absence of AdoMet to preclude conversion...
of substrate to product during the incubation. Incubation of TbCom1 with the cap 0 RNA substrate resulted in the formation of a discrete protein–RNA complex that migrated more slowly than the free RNA (Figure 5A). The abundance of this complex increased in proportion to the amount of input enzyme, with an apparent dissociation constant of ∼8 nM calculated based on (24). No specific complex was detected when TbCom1 was incubated with GpppRNA (Figure 5A). Thus, TbCom1 is capable of discriminating m7GpppN from GpppN at the substrate-binding step, confirming the importance of the N-7 methyl-guanine in substrate recognition.

To assess the binding properties of TbCom1, we performed competition assays with cap analogs. Either GTP, GpppG, m7GpppG or m7GpppA at 0.1 mM or 1 mM was pre-incubated with 0.1 μM 32P-labeled cap 0 RNA, followed by addition of TbCom1. Neither GTP nor GpppG competed efficiently for binding by TbCom1 (Figure 5B). Both m7GpppG and m7GpppA competed for cap 0 RNA-binding by TbCom1, albeit only at high concentrations; ∼80% inhibition was observed with 0.1 mM m7GpppG and 40% inhibition was observed with 0.1 mM m7GpppA. These results demonstrate that TbCom1 binds less avidly to cap analogues than to m7GpppG-terminated RNA and that the RNA chain is required for a stable interaction.

**Mutational analysis of TbCom1**

We performed a mutagenesis analysis of TbCom1 to gain insight into the structural and functional requirements for the methyltransfer reaction. The structure of VP39 shows that the active site is comprised of two ligand-binding pockets: one for AdoMet and one for the m7G cap (17–19). The AdoMet-binding pocket in VP39 consists of a network of hydrogen bonds and van der Waals interactions with the AdoMet adenine (Phe115 and Val116), ribose (Asp95, Arg97, Val139 and Arg140) or methionine (Gln39, Tyr66, Gly72, His74 and Asp138). The essential m7G-binding pocket consists of two aromatic residues (Tyr22 and Phe180), which make base-stacking interactions with the guanine ring of the m7G cap. Additional hydrogen-bonding and van der Waals interactions with m7G are made by two acidic side-chains (Asp182 and Glu233) and by the backbone carbonyl of Tyr204. Of these 16 amino acids in VP39, 15 are either identical or conserved in TbCom1 (Figure 1), suggesting that TbCom1 may utilize a similar mechanism for recognition of AdoMet and capped RNA substrates as VP39, even though the enzymes differ in the positions they methylate on the RNA.

We selected eight residues in TbCom1 for alanine-substitution: three in the putative AdoMet-binding pocket (His75, Asp142 and Arg144) and four in the putative cap-binding pocket (Tyr18, Tyr187, Asp192 and Glu253) as indicated by asterisks in Figure 1. In addition, we mutated Val115, which is conserved among kinetoplastid Com1 proteins but is absent in VP39. The mutant TbCom1 proteins were expressed and purified in parallel with wild-type proteins, their binding affinities to m7Gppp-terminated RNA were measured by gel mobility shift assay (Figure 6A), and their methyltransferase activities were compared to wild-type in the presence of 50 μM AdoMet and 0.1 μM cap 1-terminated RNA-IV (Figure 6B). The Y18A, H75A, D142A and R144A mutations reduced the methyltransferase activity to <2% of wild-type level. The Y187A and E253A proteins showed moderately reduced levels of activity (16 and 22% of wild-type level, respectively). In contrast, the V115A and D192A mutations retain near wild-type activities.

To evaluate the nature of the defect in these mutant proteins, their binding affinities to m7Gppp-terminated RNA substrates were measured by gel mobility shift assay (Figure 6C). The Y18A, Y187A and E253A mutations show significant reductions in binding to the capped RNA. By comparing the extent of binding at equivalent concentrations of proteins, we estimated that Y18A was reduced to 1% of the wild-type level. The Y187A and E253A mutants had 5–10% of wild-type binding. The H75A and V115A mutants...
The mRNAs of kinetoplastid protozoans possess a unique cap structure on the SL RNA, which is transferred to the 5′ end of all mRNAs by trans-splicing (6,11). While the enzymes that catalyze cap 0 formation in T. brucei have been characterized (25–27), the 2′-O nucleoside methyltransferase activities that lead to cap 4 have not been described. T. brucei encodes 48 and 57 kDa proteins with similarity to the vaccinia VP39 cap-dependent 2′-O nucleoside RNA methyltransferase (14). We showed that the 48 kDa recombinant TbCom1 protein transfers a methyl group from AdoMet to m′GpppN-terminated RNA at the 2′-OH position of the second nucleoside of the transcribed RNA to form m′GpppNpNm. TbCom1 is capable of methylating either cap 0- or cap 1-terminated RNA, indicating that methylation at the second nucleoside occurs after cap 0 formation but can take place prior to methylation at the first nucleoside. TbCom1 is the only cellular cap-dependent 2′-O methyltransferase that has been characterized biochemically with a unique specificity for methylating the second nucleoside of the mRNA.

TbCom1 binds stably to a 35mer m′GpppN-terminated RNA, whereas like VP39, no complex was formed with GpppN-terminated RNA (28). Thus TbCom1 is capable of discriminating methylated versus unmethylated capped RNA at the substrate-binding step. The apparent dissociation constant of TbCom1 binding to methylated capped RNA was about 8 nM, a value comparable to the affinity of VP39 with 50mer m′GpppN-RNA [K_m = 9.3 nM (28)]. We note that m′GpppA and m′GpppG cap analogues are weak competitors of TbCom1 binding to m′GpppN-RNA, suggesting that the enzyme requires a downstream RNA chain for stable interaction. The fact that TbCom1 can bind to and methylate RNA in a non-sequence dependent manner implies that 2′-O methylation can take place on RNAs other than the SL RNA, such as snRNAs and polycistronic pre-mRNAs, although it is not known whether polycistronic pre-mRNAs are capped. Alternatively, an in vivo specificity for cap 4 modification to SL RNA is achieved by the recruitment of methyltransferase components to the site of SL RNA transcription, as cap 4 formation appears to take place cotranscriptionally during SL RNA synthesis (7).

We identified 6 amino acids (Tyr18, His75, Asp142, Arg144, Tyr187 and Glu253) that are essential or important for TbCom1 methyltransferase activity. Alanine-substitution at His75, Asp142 and Arg144 in the putative AdoMet-binding motif severely reduces TbCom1 methyltransferase activity, but the mutant proteins retain the ability to bind to capped RNA. Based on the crystal structure of VP39 complexed with AdoMet, TbCom1 His75 and Asp142 (equivalent of VP39 His74 and Asp138, respectively) may form hydrogen bonds with the terminal oxygen atoms of the AdoMet methionine. The Arg144 in TbCom1 may interact with the backbone nitrogen atom of the ribose ring of AdoMet, analogous to Arg140 in VP39. Consistent with our results, the D138A-R140A double mutant in VP39 was deficient for AdoMet-binding and methyltransferase activity (29,30).

In addition to the VP39 structure, insight into the mechanism of m′G cap-recognition has been gained from the atomic structures of human nuclear cap-binding complex (CBC) and eIF4E complexed with either m′GDP or methylated cap analogues (31–33). While the overall structures of these proteins differ significantly, the guanine ring of the

DISCUSSION

The mRNAs of kinetoplastid protozoans possess a unique cap 4 structure on the SL RNA, which is transferred to the 5′ end...
cap nucleotide is sandwiched by base-stacking interactions with two aromatic residues in all three proteins: Tyr18/ Phe180 in VP39, Trp56/Trp102 in eIF4E and Tyr20/Try43 in CBP20 subunit of CBC. Perturbation of the aromaticity by mutagenesis of each of these proteins decreases the affinity, and in some cases the specifcity, for the cap structure (19,33,34). We propose that TbCom1 utilizes analogous base-stacking interactions for recognition of the m’G moiety, as mutation of the equivalent aromatic residues (Tyr18 and Tyr187) led to reduced methyltransferase activity and abolished capped RNA-binding. It is noteworthy that the Y18A mutation had a more severe effect on binding to and methylation of capped RNA than the Y187A mutation. This is in contrast to VP39, where alanine substitution at the first aromatic residue (Y22A) had a less dramatic effect on methyltransferase activity than alanine-substitution at the second aromatic residue (F180A) (19).

In addition to the base-stacking interactions, at least one acidic side-chain in TbCom1 is essential for binding to capped RNA. Alanine-substitution of Glu253 in TbCom1 led to a reduction in methyltransferase activity and cap-specific binding. The corresponding acidic residues in VP39 (Glu233), eIF4E (Glu103) and the CBP20 subunit (Asp116) interact with the N1 and/or N2 atom of the m’G purine ring via salt-bridges or hydrogen bonds (19,20,33–36). Removal of these acidic side-chains decreased cap-specific binding in all three proteins. We predict that the carboxyl side-chain of Glu253 in TbCom1 interacts with the positively charged m’G moiety to enhance cap specificity. The Asp192 side-chain of Glu253 in TbCom1 interacts with the positively charged m’G moiety to enhance cap specificity. The Asp192 side-chain of Glu253 in TbCom1 interacts with the positively charged m’G moiety to enhance cap specificity. The Asp192 side-chain of Glu253 in TbCom1 interacts with the positively charged m’G moiety to enhance cap specificity.

While our biochemical analysis of TbCom1 was in progress, genetic knockouts and RNAi-mediated knockdowns of the 48 kDa TbCOM1 and 57 kDa Tb.bruceli genes were generated (which were called TbMT48 and TbMT57, respectively) (37–39). Neither the TbCOM1/TbMT48 nor TbMT57 knockouts, or the simultaneous knockdowns of both genes, in procyclic Tb.bruceli had effects on viability or trans-splicing. Consistent with our biochemical data, TbCOM1/TbMT48-deficient cell lines lacked 2’-O-methyl transferase at position +2 on the SL RNA (38,39). In contrast, SL RNA isolated from TbMT57 deficient cell lines accumulated cap 2, implying that TbMT57 is involved in methylation at positions +3 and/or +4 on the SL RNA (37,39). However, the enzymatic activity of the TbMT57 gene product has not been characterized and thus it is not clear what is the substrate requirement for its methyltransferase activity. Further structural and functional studies of TbCom1 and the TbMT57 gene product, as well as identification of the methyltransferases responsible for SL RNA base modifications, should provide a better understanding of how cap 4 modifications are mechanistically coordinated and the role of cap 4 in kinetoplastid parasite gene expression.

ACKNOWLEDGEMENTS

The authors would like to thank Ed Niles and Paul Gollnick for critically reading the manuscript. M.P.H is a recipient of an American Heart Association Post-doctoral Fellowship. Funding to pay the Open Access publication charges for this article was provided by the State University of New York, Buffalo.

Conflict of interest statement. None declared.

REFERENCES


